Advantages of combined use of sodium-glucose co-transporter type 2 inhibitors and glucagon-like peptide-1 receptor agonists relatively to cardiovascular and renal outcomes in patients with type 2 diabetes mellitus


DOI: https://dx.doi.org/10.18565/therapy.2024.8.66-76

Salukhov V.V., Shustov S.B., Petrankov K.V.

S.M. Kirov Military Medical Academy of the Ministry of Defence of the Russian Federation, Saint Petersburg
Abstract. Modern classes of hypoglycemic drugs, such as sodium-glucose co-transporter type 2 (SGCT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists, have been shown in large-scale studies to reduce cardiovascular risk in patients with type 2 diabetes mellitus (T2DM), as well as the ability to have a positive effect on renal function. At the same time, these classes of drugs have their own peculiarities: for example, SGCT-2 inhibitors demonstrated better effects in terms of reducing hospitalizations for heart failure and decreased renal function, while GLP-1 receptor agonists to a greater extent reduced the risk of cardiovascular and cerebrovascular events. The aim of the review is to analyze the data of clinical trials and meta-analyses reflecting the effect of SGCT-2 inhibitors and GLP-1 receptor agonists, both in isolation and in combination, on cardiocerebrovascular and renal outcomes in patients with T2DM, as well as to analyze the mechanisms of drug action which predetermined obtained results.

Literature


1. Sun H., Saeedi P., Karuranga S. et al. IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res Clin Pract. 2022; 183: 109119.


https://doi.org/10.1016/j.diabres.2021.109119. PMID: 34879977. PMCID: PMC11057359.


2. Дедов И.И., Шестакова М.В., Майоров А.Ю. с соавт. Алгоритмы специализированной медицинской помощи больным сахарным диабетом / под редакцией И.И. Дедова, М.В. Шестаковой, А.Ю. Майорова. 11-й выпуск. Сахарный диабет. 2023; 26(S2): 1–157. (Dedov I.I., Shestakova M.V., Mayorov A.Yu. et al. Standards of specialized diabetes care. Ed. by Dedov I.I., Shestakova M.V., Mayorov A.Yu. 11th edition. Saharnyy diabet = Diabetes Mellitus. 2023; 26(S2): 1–157 (In Russ.)).


https://doi.org/10.14341/DM13042. EDN: DCKLCI.


3. Дедов И.И., Шестакова М.В., Викулова О.К. с соавт. Эпидемиологические характеристики сахарного диабета в Российской Федерации: клинико-статистический анализ по данным регистра сахарного диабета на 01.01.2021. Сахарный диабет. 2021; 24(3): 204–221. (Dedov I.I., Shestakova M.V., Vikulova O.K. et al. Epidemiological characteristics of diabetes mellitus in the Russian Federation: Clinical statistical analysis based on diabetes registry data as of January 1, 2021. Saharnyy diabet = Diabetes Mellitus. 2021; 24(3): 204–221 (In Russ.)).


https://doi.org/10.14341/DM12759. EDN: MEZKMG.


4. Починка И.Г., Стронгин Л.Г., Ботова С.Н. с соавт. Влияние сахарного диабета 2-го типа на 5-летнюю выживаемость пациентов, госпитализированных с острой декомпенсацией сердечной недостаточности. Кардиология. 2017; 57(9): 14–19. (Pochinka I.G., Strongin L.G., Botova S.N. et al. The impact of type 2 diabetes on the 5-year survival of patients hospitalized with acute decompensation of heart failure. Kardiologiya = Cardiology. 2017; 57(9): 14–19 (In Russ.)).


https://doi.org/10.18087/cardio.2017.9.10027. EDN: ZFBGIT.


5. Петранков К.В., Салухов В.В., Пугачев М.И. с соавт. Прогнозирование развития предиабета и сахарного диабета 2-го типа: современные подходы. Вестник Северо-Западного государственного медицинского университета им. И.И. Мечникова. 2021; 13(3): 31–42. (Petrankov K.V., Salukhov V.V., Pugachev M.I. et al. Prediction of the development of prediabetes and type 2 diabetes: Modern approaches. Vestnik Severo-Zapadnogo gosudarstvennogo meditsinskogo universiteta imeni I.I. Mechnikova = Bulletin of the North-Western State Medical University named after I.I. Mechnikov. 2021; 13(3): 31–42 (In Russ.)).


https://doi.org/.21518/2079-701X-2022-16-14-128-136. EDN: UEHQFU.


6. Салухов В.В., Халимов Ю.Ш., Шустов С.Б., Кадин Д.В. Снижение кардиоваскулярного риска у пациентов с сахарным диабетом 2 типа: обзор основных стратегий и клинических исследований. Сахарный диабет. 2018; 21(3): 193–205. (Salukhov V.V., Khalimov Yu.Sh., Shustov S.B., Kadin D.V. Reducing cardiovascular risk in patients with type 2 diabetes: A review of key strategies and clinical studies. Saharnyy diabet = Diabetes Mellitus. 2018; 21(3): 193–205 (In Russ.)).


https://doi.org/10.14341/DM9570. EDN: UYKBCG.


7. Palmer S.C., Tendal B., Mustafa R.A. et al. Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: Systematic review and network meta-analysis of randomised controlled trials. BMJ. 2021; 372: m4573.


https://doi.org/10.1136/bmj.m4573. PMID: 33441402. PMCID: PMC7804890.


8. ElSayed N.A., Aleppo G., Aroda V.R. et al.; on behalf of the American Diabetes Association. 9. Pharmacologic approaches to glycemic treatment: Standards of care in diabetes-2023. Diabetes Care. 2023; 46(Suppl 1): S140–S157.


https://doi.org/10.2337/dc23-S009. PMID: 36507650. PMCID: PMC9810476.


9. McDonagh T.A., Metra M., Adamo M. et al.; ESC Scientific Document Group. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021; 42(36): 3599–726.


https://doi.org/10.1093/eurheartj/ehab368. PMID: 34447992.


10. Kleindorfer D.O., Towfighi A., Chaturvedi S. et al. 2021 Guideline for the prevention of stroke in patients with stroke and transient ischemic attack: A guideline from the American Heart Association / American Stroke Association. Stroke. 2021; 52(7): e364–e467.


https://doi.org/10.1161/STR.0000000000000375. PMID: 34024117.


11. Аметов А.С., Невольникова А.О., Тертычная Е.С., Мишра О.А. Агонист глюкагоноподобного пептида-1 дулаглутид: в поисках «молекулы выживания». Эндокринология: новости, мнения, обучение. 2020; 9(2): 49–58. (Ametov A.S., Nevolnikova A.O., Tertychnaya E.S., Mishra O.A. Glucagon-like peptide-1 agonist dulaglutide: In search of the “survival molecule”. Endokrinologiya: novosti, mneniya, obuchenie = Endocrinology: News, Opinions, Education. 2020; 9(2): 49–58 (In Russ.)).


https://doi.org/10.33029/2304-9529-2020-9-2-49-58. EDN: JBGGUM.


12. Салухов В.В., Котова М.Е. Основные эффекты, вызываемые ингибиторами SGLT2 у больных сахарным диабетом типа 2, и механизмы, которые их определяют. Эндокринология: новости, мнения, обучение. 2019; 8(3): 61–74. (Salukhov V.V., Kotova M.E. Main effects caused by SGLT2 inhibitors in patients with type 2 diabetes and mechanisms that determine them. Endokrinologiya: novosti, mneniya, obuchenie = Endocrinology: News, Opinions, Education. 2019; 8(3): 61–74 (In Russ.)).


https://doi.org/10.24411/2304-9529-2019-13007. EDN: VJHUUU.


13. Хамнуева Л.Ю., Андреева Л.С. Эффективность лечения агонистами рецептора глюкагоноподобного пептида-1 азиатских пациентов с сахарным диабетом типа 2. Проблемы эндокринологии. 2023; 69(2): 38–46. (Khamnueva L.Yu., Andreeva L.S. Effectiveness of treatment with glucagon-like peptide-1 receptor agonists in Asian patients with type 2 diabetes mellitus. Problemy endokrinologii = Problems of Endocrinology. 2023; 69(2): 38–46 (In Russ.)).


https://doi.org/10.14341/probl13245. EDN: MEVSYN.


14. Gourdy P., Darmon P., Dievart F. et al. Combining glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2is) in patients with type 2 diabetes mellitus (T2DM). Cardiovasc Diabetol. 2023; 22(1): 79.


https://doi.org/10.1186/s12933-023-01798-4. PMID: 37005640. PMCID: PMC10067319.


15. Халимов Ю.Ш., Кузьмич В.Г. Органопротективные эффекты агонистов рецепторов глюкагоноподобного пептида 1-го типа по результатам доказательных исследований сердечно-сосудистой безопасности. Медицинский совет. 2019; (21): 189–197. (Khalimov Yu.Sh., Kuzmich V.G. Organoprotective effects of glucagon-like peptide-1 receptor agonists based on evidence from cardiovascular safety studies. Meditsinskiy sovet = Medical Council. 2019; (21): 189–197 (In Russ.)).


https://doi.org/10.21518/2079-701X-2019-21-189-197. EDN: LTSLRL.


16. Ильинская Т.А., Салухов В.В., Минаков А.А. Влияние современной сахароснижающей терапии на массу тела у больных сахарным диабетом 2 типа. Эндокринология: новости, мнения, обучение. 2022; 11(1): 39–52. (Ilyinskaya T.A., Salukhov V.V., Minakov A.A. The impact of modern hypoglycemic therapy on body weight in patients with type 2 diabetes mellitus. Endokrinologiya: novosti, mneniya, obuchenie = Endocrinology: News, Opinions, Education. 2022; 11(1): 39–52 (In Russ.)).


https://doi.org/10.33029/2304-9529-2022-11-1-39-52. EDN: KAKSRW.


17. Ferrannini G., Hach T., Crowe S. et al. Energy balance after sodium-glucose cotransporter 2 inhibition. Diabetes Care. 2015; 38(9): 1730–35.


https://doi.org/10.2337/dc15-0355. PMID: 26180105. PMCID: PMC4542276.


18. Hollander P., Bays H.E., Rosenstock J. et al. Coadministration of canagliflozin and phentermine for weight management in overweight and obese individuals without diabetes: A randomized clinical trial. Diabetes Care. 2017; 40(5): 632–39.


https://doi.org/10.2337/dc16-2427. PMID: 28289041.


19. Халимов Ю.Ш., Рубцов Ю.Е., Салухов В.В., Агафонов П.В. Ингибиторы натрий-глюкозного транспортера 2-го типа и новые возможности управления сосудистым возрастом у больных сахарным диабетом 2-го типа. Медицинский совет. 2021; (12): 228–236. (Khalimov Yu.Sh., Rubtsov Yu.E., Salukhov V.V., Agafonov P.V. Sodium-glucose cotransporter 2 inhibitors and new opportunities for managing vascular age in patients with type 2 diabetes mellitus. Meditsinskiy sovet = Medical Council. 2021; (12): 228–236 (In Russ.)).


https://doi.org/10.21518/2079-701X-2021-12-228-236. EDN: SYOSSN.


20. Мкртумян А.М., Маркова Т.Н., Мищенко Н.К. Кардиопротективные механизмы ингибиторов натрий-глюкозного котранспортера 2 типа. Сахарный диабет. 2021; 24(3): 291–299. (Mkrtumyan A.M., Markova T.N., Mishchenko N.K. Cardioprotective mechanisms of sodium-glucose cotransporter 2 inhibitors. Saharnyy diabet = Diabetes Mellitus. 2021; 24(3): 291–299 (In Russ.)).


https://doi.org/10.14341/DM12541. EDN: QMVGGX.


21. Симаненкова А.В., Минасян С.М., Каронова Т.Л. с соавт. Сравнительная оценка кардиопротективных свойств эмпаглифлозина, канаглифлозина и ситаглиптина у крыс с экспериментальным сахарным диабетом 2 типа. Сахарный диабет. 2021; 24(2): 111–121. (Simanenkova A.V., Minasyan S.M., Karonova T.L. et al. Comparative assessment of the cardioprotective properties of empagliflozin, canagliflozin, and sitagliptin in rats with experimental type 2 diabetes mellitus. Saharnyy diabet = Diabetes Mellitus. 2021; 24(2): 111–121 (In Russ.)).


https://doi.org/10.14341/DM12714. EDN: ZZQPYG.


22. Гришаев С.Л., Черкашин Д.В., Салухов В.В., Аланичев А.Е. Современные стратегии терапии СД 2 у пациентов со стабильной ишемической болезнью сердца. Старые цели, новые возможности (обзор литературы). Российский кардиологический журнал. 2024; 29(2): 98–106. (Grishaev S.L., Cherkashin D.V., Salukhov V.V., Alanichev A.E. Modern strategies for the treatment of type 2 diabetes in patients with stable ischemic heart disease. Old targets, new opportunities (literature review). Rossijskiy kardiologicheskiy zhurnal = Russian Journal of Cardiology. 2024; 29(2): 98–106 (In Russ.)).


https://doi.org/10.15829/1560-4071-2024-5689. EDN: NGLELH.


23. Chen Y.-C., Jandeleit-Dahm K., Peter K. Sodium-glucose co-transporter 2 (SGLT2) inhibitor dapagliflozin stabilizes diabetes-induced atherosclerotic plaque instability. J Am Heart Assoc. 2022; 11(1): e022761.


https://doi.org/10.1161/jaha.121.022761. PMID: 34970931. PMCID: PMC9075188.


24. Ludvik B., Frías J.P., Tinahones F.J. et al. Dulaglutide as add-on therapy to SGLT2 inhibitors in patients with inadequately controlled type 2 diabetes (AWARD-10): A 24-week, randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol. 2018; 6(5): 370–81.


https://doi.org/10.1016/S2213-8587(18)30023-8. PMID: 29483060.


25. Frías J.P., Guja C., Hardy E. et al. Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): A 28 week, multicentre, double-blind, phase 3, randomised controlled trial. Lancet Diabetes Endocrinol. 2016; 4(12): 1004–16.


https://doi.org/10.1016/S2213-8587(16)30267-4. PMID: 27651331.


26. Zinman B., Bhosekar V., Busch R. et al. Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): A randomised, placebo-controlled trial. Lancet Diabetes Endocrinol. 2019; 7(5): 356–67.


https://doi.org/10.1016/S2213-8587(19)30066-X. PMID: 30833170.


27. Lundkvist P., Sjöström C.D., Amini S. et al. Dapagliflozin once-daily and exenatide once-weekly dual therapy: A 24-week randomized, placebo-controlled, phase II study examining effects on body weight and prediabetes in obese adults without diabetes. Diabetes Obes Metab. 2017; 19(1): 49–60.


https://doi.org/10.1111/dom.12779. PMID: 27550386. PMCID: PMC5215525.


28. Guo M., Gu J., Teng F. et al. The efficacy and safety of combinations of SGLT2 inhibitors and GLP-1 receptor agonists in the treatment of type 2 diabetes or obese adults: A systematic review and meta-analysis. Endocrine. 2020; 67(2): 294–304.


https://doi.org/10.1007/s12020-019-02175-6. PMID: 31900793.


29. Lam C.S.P., Ramasundarahettige C., Branch K.R.H. et al. Efpeglenatide and clinical outcomes with and without concomitant sodium-glucose cotransporter-2 inhibition use in type 2 diabetes: Exploratory analysis of the AMPLITUDE-O trial. Circulation. 2022; 145(8): 565–74.


https://doi.org/10.1161/circulationaha.121.057934. PMID: 34775781.


30. Holman R.R., Bethel M.A., Mentz R.J. et al.; EXSCEL Study Group. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2017; 377(13): 1228–39.


https://doi.org/10.1056/NEJMoa1612917. PMID: 28910237. PMCID: PMC9792409.


31. Clegg L.E., Penland R.C., Bachina S. et al. Effects of exenatide and open-label SGLT2 inhibitor treatment, given in parallel or sequentially, on mortality and cardiovascular and renal outcomes in type 2 diabetes: Insights from the EXSCEL trial. Cardiovasc Diabetol. 2019; 18(1): 138.


https://doi.org/10.1186/s12933-019-0942-x. PMID: 31640705. PMCID: PMC6805385.


32. Wiviott S.D., Raz I., Bonaca M.P. et al.; DECLARE-TIMI 58 Investigators. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019; 380(4): 347–57.


https://doi.org/10.1056/NEJMoa1812389. PMID: 30415602.


33. Cahn A., Wiviott S.D., Mosenzon O. et al. Cardiorenal outcomes with dapagliflozin by baseline glucose-lowering agents: Post hoc analyses from DECLARE-TIMI 58. Diabetes Obes Metab. 2021; 23(1): 29–38.


https://doi.org/10.1111/dom.14179. PMID: 32844557.


34. Gerstein H.C., Sattar N., Rosenstock J. et al.; AMPLITUDE-O Trial Investigators. Cardiovascular and renal outcomes with efpeglenatide in type 2 diabetes. N Engl J Med. 2021; 385(10): 896–907.


https://doi.org/10.1056/NEJMoa2108269. PMID: 34215025.


35. Dave C.V., Kim S.C., Goldfine A.B. et al. Risk of cardiovascular outcomes in patients with type 2 diabetes after addition of SGLT2 inhibitors versus sulfonylureas to baseline GLP-1RA therapy. Circulation. 2021; 143(8): 770–79.


https://doi.org/10.1161/circulationaha.120.047965. PMID: 33302723. PMCID: PMC7902404.


36. Wright A.K., Carr M.J., Kontopantelis E. et al. Primary prevention of cardiovascular and heart failure events with SGLT2 inhibitors, GLP-1 receptor agonists, and their combination in type 2 diabetes. Diabetes Care. 2022; 45(4): 909–18.


https://doi.org/10.2337/dc21-1113. PMID: 35100355.


37. Loyo P.L., Bohra C., Bhatia K. et al. Additive cardiovascular risk reduction of GLP1 and SGLT2I in diabetic patients with atherosclerotic disease. J Am Coll Cardiol. 2022; 79(9): 1430.


https://doi.org/10.1016/S0735-1097(22)02421-4.


38. Marfella R., Prattichizzo F., Sardu C. et al. GLP-1 receptor agonists-SGLT-2 inhibitors combination therapy and cardiovascular events after acute myocardial infarction: An observational study in patients with type 2 diabetes. Cardiovasc Diabetol. 2024; 23(1): 10.


https://doi.org/10.1186/s12933-023-02118-6. PMID: 38184582. PMCID: PMC10771648.


39. Simms-Williams N., Treves N., Yin H. et al. Effect of combination treatment with glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors on incidence of cardiovascular and serious renal events: Population based cohort study. BMJ. 2024; 385: e078242.


https://doi.org/10.1136/bmj-2023-078242. PMID: 38663919. PMCID: PMC11043905.


40. Li C., Luo J., Jiang M., Wang K. The efficacy and safety of the combination therapy with GLP-1 receptor agonists and SGLT-2 inhibitors in type 2 diabetes mellitus: A systematic review and meta-analysis. Front Pharmacol. 2022; 13: 838277.


https://doi.org/10.3389/fphar.2022.838277. PMID: 35185588. PMCID: PMC8854770.


41. Симаненкова А.В., Фукс О.С., Тимкина Н.В. с соавт. Нейропротективные эффекты сахароснижающих препаратов на модели фокальной ишемии – реперфузии головного мозга у крыс. Артериальная гипертензия. 2023; 29(6): 579–592. (Simanenkova A.V., Fuks O.S., Timkina N.V. et al. Neuroprotective effects of hypoglycemic agents in a model of focal ischemia-reperfusion in the brain of rats. Arterial’naya gipertenziya = Arterial Hypertension. 2023; 29(6): 579–592 (In Russ.)).


https://doi.org/10.18705/1607-419X-2023-29-6-579-592. EDN: BWYQSY.


42. Шамхалова М.Ш., Скляник И.А., Шестакова М.В. Нефропротективный потенциал агонистов рецепторов глюкагоноподобного пептида 1. Сахарный диабет. 2020; 23(1): 56–64. (Shamkhalova M.Sh., Sklyanik I.A., Shestakova M.V. Nephroprotective potential of glucagon-like peptide-1 receptor agonists. Saharnyy diabet = Diabetes Mellitus. 2020; 23(1): 56–64 (In Russ.)).


https://doi.org/10.14341/DM12379. EDN: QEZDWA.


43. de Boer I.H., Khunti K., Sadusky T. et al. Diabetes management in chronic kidney disease: A consensus report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2022; 102(5): 974–89.


https://doi.org/10.1016/j.kint.2022.08.012. PMID: 36202661.


44. Игнатова Ю.С., Шустер С.Ю., Печерина Т.Б., Барбараш О.Л. Антифибротические эффекты ингибиторов натрий-глюкозного котранспортера 2-го типа (SGLT2) у пациентов с сердечной недостаточностью. Российский кардиологический журнал. 2024; 29(1): 82–88. (Ignatova Yu.S., Shuster S.Yu., Pecherina T.B., Barbarash O.L. Antifibrotic effects of sodium-glucose cotransporter 2 inhibitors (SGLT2) in patients with heart failure. Rossiyskiy kardiologicheskiy zhurnal = Russian Journal of Cardiology. 2024; 29(1): 82–88 (In Russ.)).


https://doi.org/10.15829/1560-4071-2024-5580. EDN: USRZZV.


45. Sridhar V.S., Dubrofsky L., Boulet J., Cherney D.Z. Making a case for the combined use of SGLT2 inhibitors and GLP1 receptor agonists for cardiorenal protection. J Bras Nefrol. 2020; 42(4): 467–77.


https://doi.org/10.1590/2175-8239-JBN-2020-0100. PMID: 32926067. PMCID: PMC7860654.


About the Autors


Vladimir V. Salukhov, MD, Dr. Sci. (Medicine), professor, head of the 1st Department and clinic (therapy, advanced training for physicians) named after academician N.S. Molchanov, S.M. Kirov Military Medical Academy of the Ministry of Defenсe of the Russian Federation. Address: 194044, Saint Petersburg, 6 Akademika Lebedeva St.
E-mail: vlasaluk@yandex.ru
ORCID: https://orcid.org/0000-0003-1851-0941. eLibrary SPIN: 4531-6011
Sergey B. Shustov, MD, Dr. Sci. (Medicine), professor, professor of the 1st Department and clinic (therapy, advanced training for physicians) named after academician N.S. Molchanov, S.M. Kirov Military Medical Academy of the Ministry of Defence of the Russian Federation. Address: 194044, Saint Petersburg, 6 Akademika Lebedeva St.
E-mail: sbs5555@mail.ru
ORCID: https://orcid.org/0000-0002-9075-8274. eLibrary SPIN: 5237-2036
Kirill V. Petrankov, MD, PhD (Medicine), endocrinologist at the 1st Department (therapy, advanced training for physicians), S.M. Kirov Military Medical Academy of the Ministry of Defence of the Russian Federation. Address: 194044, Saint Petersburg, 6 Akademika Lebedeva St.
E-mail: petrankovk@yandex.ru
ORCID: https://orcid.org/0000-0001-7244-4303. eLibrary SPIN: 7775-3011


Similar Articles


Бионика Медиа